A comprehensive pipeline enables storage, retrieval and analysis of clinical data, which is fed into the genomics platform that is expected to contribute towards the identification of specific disease markers or traits. The genomics platform uses Affymetrix chips in the discovery and analysis of DNA polymorphisms and in the analysis of the Transcriptome. Proteomics and Metabolomics enable the identification of biomarkers by utilizing high-throughput techniques including Mass Spectroscopy. The data generated from these platforms is hosted and supported with high-end servers.
Breast Cancer Testing for dozens of biomarkers means oncologists can fine-tune breast cancer treatments in ways not even dreamed of just an eye-blink ago.
The symptoms were of grave concern, as the patient had previously undergone surgery for breast cancer that had spread to her brain. Loghin ordered testing of that fluid to see if the patient might have certain biomarkers that could be targeted by existing drugs.
A biomarker is a DNA sequence or protein associated with the disease; different biomarkers can suggest specific treatments, depending on the disease and other factors. She asked for tests that could detect tumor cells circulating in the blood. The cancer cells in the fluid also had a lot of HER2, a protein associated with aggressive breast cancers but also treatable with a drug called Herceptin trastuzumab.
The drug is usually taken intravenously, but Loghin had heard of a couple of cases in which Herceptin was delivered directly into the cerebrospinal fluid via a flexible tube, or catheter. The patient agreed to this experimental treatment. It took only a week for the news to improve.
Within a few weeks, her cancer cell numbers had fallen so low that her immune system had begun to take over, clearing out the remaining cancer cells.
Nearly two and a half years later, the patient is still alive and well enough to do yoga. Another MD Anderson patient who had a similar disease profile and therapy is also alive and well one year after treatment. This case outlines the dream of personalized medicine: A disease is analyzed at the molecular level.
The analysis identifies a drug target. The drug gets delivered where it needs to go.
The patient gets better. And while this hopeful scenario has yet to become commonplace, it is becoming more and more the norm for many breast cancer patients. As it relates to breast cancer, such a targeted approach to treatment is increasingly possible.
In the next few years, patients with breast cancer can expect increasingly detailed diagnostic tests, tests that may predict side effects of treatments like chemotherapy or radiation, and better guidance in choosing the drug, or drugs, most likely to eradicate their disease. Genomic discoveries may also help patients with advanced, aggressive cancers, a group for whom even the latest treatments often fail.
In these ways and many others, breast cancer prevention, treatment, and care are a microcosm of the slow but inevitable shift in healthcare.
Early Progress All cancers are caused by genetic mutations that somehow confer an advantage on the cancer cells, causing — or simply allowing — them to grow out of control.In April , headlines around the world announced a momentous scientific achievement: the completion of the Human Genome attheheels.com international consortium of researchers had finished compiling the sequence of 3 billion base pairs — or letters that spell out the genetic code — in .
The Cancer Genome Atlas researchers are mapping the genetic changes in 33 cancers. Find out which cancers have been selected for study, the criteria for selection and the scientific questions being asked about each cancer.
The Cancer Genome Atlas (TCGA) TCGA is a joint effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), which are both part of the National Institutes of Health, U.S.
Department of Health and Human Services. Late Professor Joel Kubby used adaptive optics for biological imaging, applying technology originally developed for astronomy to enable deeper imaging of tissue at higher resolutions. The Cancer Genome Atlas (TCGA) is a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing.
World Cancer Research Day. NCI's Center for Global Health supports efforts at NCI and elsewhere to further research that will lessen the burden of cancer worldwide.
|International Cancer Genome Consortium||It also nicely coincided with another historic feat in biology:|
|Fifteen-year federal project||Goals[ edit ] The goal of the pilot project was to demonstrate that advanced genomic technologies could be utilized by a team of scientists from various institutions to generate statistically and biologically significant conclusions from the genomic data set generated.|